Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).

@article{Klootwijk1998ReductionOR,
  title={Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).},
  author={Peter Klootwijk and Simon Meij and Rein Melkert and Timo Lenderink and Maarten L. Simoons},
  journal={Circulation},
  year={1998},
  volume={98 14},
  pages={
          1358-64
        }
}
BACKGROUND In the CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) trial, 1265 patients with refractory unstable angina were treated with abciximab or placebo, in addition to standard treatment from 16 to 24 hours preceding coronary intervention through 1 hour after intervention. To investigate the incidence of recurrent ischemia and the ischemic burden, a subset of 332 patients (26%) underwent continuous vector-derived 12-lead ECG-ischemia monitoring. METHODS AND… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES